Start
•
Completion

ECT vs. Esketamine

WithdrawnRegisteredCTG

This longitudinal, randomized controlled trial (n=0, withdrawn) compares the efficacy of Electroconvulsive Therapy (ECT) and intranasal esketamine in patients with Treatment-Resistant Depression (TRD).

Details

Randomised, parallel-group trial comparing intranasal esketamine (twice weekly, up to 8 sessions) versus ECT (three times weekly, up to 12 sessions) in inpatients with treatment-resistant depression at Medical University Innsbruck.

Primary aims include effectiveness for depressive symptoms and effects on brain connectivity and structure assessed by functional MRI; treatment period is up to 4 weeks with imaging and clinical follow-up.

Topics:Treatment-Resistant Depression (TRD)

Registry

Registry linkNCT04924257